Table 1.
Bivalent Vaccine Cervarix® |
4-Valent Vaccine Gardasil® |
9-Valent Vaccine Gardasil9® |
|
---|---|---|---|
Target HPV types | HPV 16/18 (HR-HPV) | HPV 6/11 (LR-HPV) HPV 16/18 (HR-HPV) |
HPV 6/11 (LR-HPV) HPV 16/18/31/33/45/52 (HR-HPV) |
Schedule | Over 10 years 0, 1, and 6 months |
Over 9 years 0, 2, and 6 months |
Over 9 years 0, 2, and 6 months |
VLP dose | L1 dose 20/20 μg | L1 dose 20/40/40/20 μg | L1 dose 30/30/60/40/20/20/20/20/20 μg |
Adjuvant | 500 μg aluminum hydroxide, 50 μg 3-O-deacylated-4-monophosphoryl lipid A |
225 μg aluminum hydroxyphosphate sulfate | 500 μg aluminum hydroxyphosphate sulfate |
VLP, virus-like particle; HR-HPV, high-risk HPV type; LR-HPV, low-risk HPV type.